SARCOMA

This study tests whether using a fluorescent dye called indocyanine green during surgery helps surgeons see and remove all sarcoma tissue, reducing the chance that cancer cells are left behind. About 90 adults with intermediate-to-high grade sarcoma of the trunk or limbs will tak…

This study tests a drug called zanidatamab in adults with certain advanced cancers (lung, colorectal, head and neck, sarcoma, or endometrial) that have a specific change in the HER2 gene. The goal is to see if the drug can shrink tumors. Participants receive the drug by IV every …

This program offers the investigational drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of approved treatments and cannot join a clinical trial. It is not a cure but aims to control the disease. Patients must get approval from …

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This early-phase study tests a new treatment called B7-H3 CAR T cells in children and young adults whose solid tumors (like neuroblastoma, sarcoma, or osteosarcoma) have come back or not responded to standard therapies. The treatment involves taking a patient's own immune cells, …

This study tests a new type of radiation therapy (SFRT) given before surgery for people with large soft tissue sarcomas (at least 5 cm) in the arm, leg, or trunk. The goal is to see if this approach can improve the chance of being cancer-free one year after treatment. About 22 ad…

This study is for people with soft tissue sarcoma who need radiation before surgery. It compares a standard 14-session radiation schedule with a shorter 5-session schedule to see if the shorter course causes fewer wound complications after surgery while still controlling the tumo…

This study tests if pembrolizumab, a drug that helps the immune system attack cancer, can shrink tumors in people with ultra-rare sarcomas. About 32 adults with specific rare sarcoma types will receive the drug. The goal is to see if it works and has mild side effects.

This study tests a new drug combination for people with advanced bone or soft tissue sarcoma that has worsened after standard treatment. The combo includes a nano-form of chemotherapy and targeted drugs chosen by tumor type. The goal is to shrink tumors and reduce side effects. A…

This study tests a drug called atezolizumab in about 200 adults with advanced solid tumors (like breast, lung, or colon cancer) whose tumor DNA suggests the drug might help. Participants get the same dose every 3 weeks, and researchers check if their cancer shrinks or stops growi…

This early-phase study tests a new treatment called PeptiCRAd-1, a virus designed to train the immune system to attack cancer cells, combined with the immunotherapy drug pembrolizumab. About 15 adults with certain advanced solid tumors (like melanoma, lung cancer, or sarcoma) wil…

This study tests whether a single-use negative pressure wound dressing (PICO 14) can reduce wound complications after surgery for soft tissue sarcoma in the arms or legs. The trial involves 48 adults who have had radiation therapy before surgery. Participants are randomly assigne…

This early-stage study tests a drug called TURALIO (pexidartinib) in people aged 3 to 35 whose cancer (like leukemia or solid tumors) has not responded to standard treatments. The main goal is to find a safe dose and see if it can shrink tumors or stop them from growing. Particip…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This early-stage study tests a new drug called SLV-154 in about 70 adults with advanced solid tumors that have spread. The main goal is to find the safest dose and check for side effects. Participants have cancers like head and neck, lung, breast, or ovarian cancer that haven't r…

This early-stage trial tests a new treatment called LauT-1 for people with advanced melanoma (a type of skin cancer) or sarcoma (a rare cancer of connective tissues). The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer …

This study tests whether adding the immunotherapy drug pembrolizumab to a targeted chemotherapy infusion (ILI with melphalan and dactinomycin) can safely delay cancer growth in people with advanced sarcoma in an arm or leg. About 30 participants aged 12 and older will receive the…

This early-phase study tests whether a new treatment combining radiation and specially engineered immune cells (B7-H3-CAR T cells) is safe for children and young adults up to age 21 with sarcomas that have come back or not responded to standard therapy. About 42 participants will…

This study tests whether the drug nivolumab can be safely given after a half-matched bone marrow transplant to help prevent sarcoma from returning. It includes children and young adults (ages 1 to 50) with high-risk, recurrent, or hard-to-treat sarcomas. Researchers will monitor …

This study tests a new drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults with can…

This program provides early access to two investigational immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers such as colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who hav…

This study is for people aged 65-100 with advanced or metastatic leiomyosarcoma, a rare soft tissue cancer that cannot be removed by surgery. Researchers want to see if giving the standard chemotherapy drug doxorubicin at a lower dose every week (instead of a higher dose every fe…

This study tests a procedure called chemoembolization for people with non-small cell lung cancer or lung tumors that have spread from other cancers. Doctors inject chemotherapy directly into the artery feeding the tumor, then block that artery with tiny beads. This traps the chem…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive cancers that have spread and no longer respond to other treatments. About 100 people will take part, and researchers will track whether tumors shrink and how long the benefit lasts. The goal i…

This early-phase study tests a new drug called CRD3874-SI in people with advanced solid tumors, including sarcoma and Merkel cell carcinoma. The main goal is to find the safest dose and see if it can shrink tumors. About 81 participants will receive different doses to check side …

This study tests a new experimental drug called GI-101, given alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with canc…

This early-phase study tests a new drug, KIVU-107, in about 76 adults with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells. The main goal is to find the…

This study tests a new drug called PEEL-224 combined with two standard chemotherapy drugs (vincristine and temozolomide) in adolescents and young adults whose sarcomas have returned or not responded to prior treatment. The goal is to find the safest dose and see if the combinatio…

This early-stage study is testing whether a new type of immune cell therapy, called HER2-CAR T cells, combined with drugs that boost the immune system (pembrolizumab or nivolumab), is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before th…

This study tests a new treatment called EBNK-001, which uses donor immune cells (natural killer cells) to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive these cells alon…

This study tests whether adding an experimental immune-boosting drug (retifanlimab) to standard chemotherapy (gemcitabine and docetaxel) can help control advanced soft tissue sarcoma that has spread or cannot be removed by surgery. About 98 adults with this rare cancer will recei…

This study tests whether combining two drugs—ATRA and cemiplimab—can shrink or slow advanced leiomyosarcoma, a rare soft-tissue cancer. About 16 adults whose cancer worsened after standard chemotherapy will receive ATRA pills for 3 days before each cemiplimab infusion, then cemip…

This study is testing a new treatment that uses a radioactive substance to target and destroy cancer cells in people with advanced solid tumors (like pancreatic, stomach, or ovarian cancer) that have not responded to standard treatments. The therapy works by attaching to a protei…

This study offers expanded access to an experimental treatment called DNG64-CAR-V for people with advanced pancreatic cancer, sarcoma, or breast cancer. Up to 40 patients will receive the therapy intravenously or directly into tumors, alone or with other approved cancer drugs. Th…

This early-phase trial tests a new treatment for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line therapy. The treatment involves taking a patient's own immune cells, modifying them in the lab to better recognize and atta…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests whether a special type of radiation called GRID, given before standard radiation and surgery, is safe and effective for people with soft tissue sarcoma in their arms or legs. The goal is to improve tumor removal and reduce the chance of the cancer coming back, wi…

This study tests an experimental oral drug called ABSK043 in about 20 people with advanced angiogenic sarcomas (intimal sarcoma, head/neck angiosarcoma, or EHE). The drug blocks a protein called PD-L1 to help the immune system attack cancer cells. The main goal is to see if the d…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study is testing whether a safe green dye, called ICG, can help surgeons see which lymph nodes might contain cancer in children with solid tumors. About 10 children will receive the dye during surgery, and doctors will check if it makes the right lymph nodes glow. The goal i…

This study is testing a new type of PET scan that uses a special tracer to find cancers like pancreatic, breast, lung, and others. The goal is to see if this scan can better detect and stage tumors compared to standard scans. About 26 adults with suspected or confirmed cancer, pl…

This study tests whether a fluorescent dye called indocyanine green (ICG) can help surgeons identify leftover tumor tissue during sarcoma removal surgery. About 110 adults with bone or soft tissue sarcomas will receive the dye before surgery, and a special camera will check for g…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early and tell which type it is. In people with lung cancer, the test will also check for any cancer…

This study tests whether a smartphone app that connects young adults (ages 18-40) with trained peer navigators can help them feel more in control of their health after finishing cancer treatment. About 138 people who had breast cancer, testicular cancer, lymphoma, or sarcoma will…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better than standard radiation and whether it helps the immune system attack cancer cells. Abo…

This study looks at whether offering mental healthcare early during sarcoma treatment can help reduce depression and anxiety and improve quality of life. About 60 adults with bone or soft tissue sarcoma who are scheduled for surgery will take part. Researchers will check how many…

This study tests whether a personalized pre-surgery program—including physical therapy, nutrition, and exercise—helps people with bone or soft-tissue sarcoma of the arm or leg recover better after tumor removal. About 53 participants will be followed for up to 24 months after sur…

This study tests a digital health program called AYA STEPS for adolescent and young adult cancer survivors. The program helps manage symptoms like pain, fatigue, and emotional distress, and encourages engagement with recommended follow-up care. Researchers will enroll 260 people …

This study tests whether the drug riluzole can prevent memory and thinking problems (often called 'chemo brain') in people receiving chemotherapy for various cancers. About 24 adults with breast, lung, or other cancers will receive either riluzole or a placebo during their chemo.…

This study looks at whether a structured exercise program can help children, teens, and young adults (ages 12-39) with sarcoma complete more of their planned chemotherapy. Participants will either exercise or receive standard care. The goal is to see if exercise is feasible and h…

This study watches how children and their caregivers recover after major cancer surgery using smartwatches and questionnaires. It also looks at blood proteins and metabolites linked to stress. The goal is to find patterns that show how well a child is bouncing back, so doctors ca…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can find cancer early after treatment. Researchers will follow about 100 people with different solid tumors, plus healthy volunteers, to see if the test helps predict when cancer comes back. …

This study tests whether a smartwatch combined with artificial intelligence can detect early signs of heart damage in people who have had lymphoma or sarcoma. Researchers will monitor 250 survivors over a year using mobile ECGs and the Apple Watch. The goal is to find a simple, c…

This study is looking for a way to diagnose and track soft tissue sarcoma using a blood test instead of repeated tissue biopsies. Researchers will collect blood and tumor samples from 50 adults with sarcoma to see if DNA from the tumor found in the blood can help doctors monitor …

This study collects extra blood, tissue, and urine samples from children and adults with childhood cancers like leukemia and brain tumors. The goal is to create a large repository for researchers to study the biology of these cancers. No extra procedures are needed—samples are ta…

This study is testing a blood test called a liquid biopsy to see if it can detect tumor DNA in people with bone or soft tissue sarcoma. Researchers will collect blood samples before, during, and after treatment to track how well the test works. The goal is to find a less invasive…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of mu…

This study looks at whether watching short educational videos about sarcoma before a first doctor's appointment helps patients and their caregivers feel more informed and satisfied. About 100 adults with advanced sarcoma (or their caregivers) who have not yet had treatment will w…

This study is creating a registry to collect detailed information on children and young adults (up to age 26) who receive radiation therapy for sarcoma or brain tumors. The goal is to track their health over time, including survival and side effects, to better understand the long…

This study looks at how a sarcoma diagnosis and its treatment affect people over the long term. Researchers will review medical records and ask patients about their health and lifestyle. The goal is to learn more about the challenges survivors face, without providing any new trea…

This study watches how people with gastrointestinal or sarcoma cancers do on standard treatments like radiation. It collects information on cancer return and side effects to help doctors improve care. About 180 adults will take part, and no experimental drugs are given.

This study aims to see if a smartphone app can help track recovery in 800 sarcoma patients after surgery. Participants will fill out health questionnaires and let the app monitor their steps and activity for a year. The goal is to better understand how patients heal and improve f…

This study aims to create immune organoids—miniature lab-grown models of the immune system—using cells from children and young adults with brain tumors, kidney tumors, neuroblastoma, or sarcoma. Researchers will take blood or tissue samples and turn them into stem cells, then gro…

This study is creating a large national database in France to collect medical and biological information from up to 150,000 people with sarcoma, a rare type of cancer. The goal is to track how patients are treated and what happens to them over time, helping researchers learn more…

This study is collecting tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new markers that link tumor genetics and immune response to how the disease behaves. Participa…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is a registry that will collect information from up to 9,000 people in Germany with sarcoma or carcinosarcoma. Researchers will track what treatments patients receive and how they do over time. The goal is to better understand these rare cancers, not to test a new trea…

This study is gathering tissue samples and medical information from 800 people with high-risk soft tissue sarcomas. The goal is to learn how to personalize chemotherapy before surgery, using genetic and protein profiles. Participants either receive standard chemo plus surgery or …

This study aims to see if watching a video before genetic testing helps people with certain cancers better understand their hereditary cancer risk. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Resear…

This study looks at the long-term quality of life, medical care satisfaction, and unmet needs of people who have lived with sarcoma for at least 5 years. Researchers will survey 1,600 adults in Germany, with or without active disease, and interview up to 60 participants. The goal…

This study analyzes tumor tissue from up to 12,000 cancer patients to identify gene mutations. The goal is to match each patient with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to improve future cancer …

This study aims to see if a 3-month daily survey method is practical for understanding chronic pain and opioid use in adolescent and young adult sarcoma survivors. About 40 participants aged 12-24 at diagnosis, now in survivorship care with meaningful pain, will complete brief da…